close
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Akamis Bio

Akamis Bio Receives FDA Fast Track Designation for NG-350A for the Treatment of Mismatch Repair-Proficient Locally Advanced Rectal Cancer
From Akamis Bio
Via Business Wire
Akamis Bio Announces the Appointment of Andrew Hirsch to the Company’s Board of Directors
From Akamis Bio
Via Business Wire
Akamis Bio Broadens Leadership Team with Key Executive Appointments
From Akamis Bio
Via Business Wire
Akamis Bio Announces Enrollment of First Patient in Phase 1b FORTRESS Trial of NG-350A in Patients with Locally Advanced Rectal Cancer
From Akamis Bio
Via Business Wire
Akamis Bio Announces $60 Million in Funding Linked to Series A Prime Financing and New Strategic Partnership
From Akamis Bio
Via Business Wire
Akamis Bio Announces Publication Detailing Initial Proof of Mechanism for NG-350A, an IV-Dosed Tumor Gene Therapy Delivering a CD40 Agonist Payload
From Akamis Bio
Via Business Wire
Akamis Bio Highlights Data Showing Potential of its Adenovirus Vector Technology in Combination with Radiation to Treat Advanced Rectal Cancer
From Akamis Bio
Via Business Wire
Akamis Bio Strengthens Leadership Team with Key Executive Appointments
From Akamis Bio
Via Business Wire
Akamis Bio, Parker Institute for Cancer Immunotherapy, and Cancer Research Institute Announce Expanded Partnership to Advance Novel Treatments for Pancreatic Cancer
From Akamis Bio
Via Business Wire
Akamis Bio Announces $30 Million Financing, Provides Clinical Program Update and Relaunches with Name Change from PsiOxus Therapeutics
From Akamis Bio
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Starting at $3.75/week.

Subscribe Today